Supporting Innovation and Global Expansion in Cannabis Testing
Claret Capital Partners is pleased to announce our investment through Fund IV in ACT LAB, a leading U.S.-based cannabis and hemp testing lab network.
Founded in 2010, ACT LAB has operations in six U.S. states, bringing deep technical expertise and real-world operational experience across cannabis, hemp, and emerging cannabinoid products. The organisation, which opened its first lab in Illinois in 2015, has developed a national testing footprint built on long-standing relationships across cultivators, processors, and finished-goods manufacturers.
As cannabis regulation continues to rapidly evolve, both the United States and Europe represent substantial long-term growth opportunities. The U.S. cannabis testing market is projected to more than double by 2032, whilst Europe is emerging as the next major expansion market as regulatory frameworks continue to develop.
With Claret’s strategic backing, ACT LAB is poised to deepen its research capabilities, introduce cutting-edge services, and expand its geographic presence to better serve the cannabis and hemp industry worldwide.
Daniel Mallon, Principal at Claret Capital Partners, commented:
“We’re delighted to support ACT LAB as they continue to expand their platform and pursue their next stage of growth. The team consistently continues to be a leader in standard setting for the cannabis and hemp testing markets. We look forward to partnering with them as they scale both in the US and Europe.”
Michael Drozd, CEO at ACT LAB, said:
“ACT LAB has a proven track record of delivering consistent, reliable, and science-driven testing for the cannabis, hemp, and wellness product industries. This investment by Claret Capital Partners supports ACT LAB’s continued growth strategy with the goal of advancing these industries and ensuring product safety for patients and consumers.”
ACT LAB marks Claret’s latest life sciences investment and reinforces our commitment to backing innovative companies shaping the future of diagnostics, testing, and scientific excellence globally.
